ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC
{{output}}
Background/aim: Randomized trials have shown the benefit of combining tyrosine kinase inhibitors (TKI) and chemotherapy in the treatment of epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC). For anaplasti... ...
